Overview

PTX-35 in Patients With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care

Phase:

Phase 1

Details

Lead Sponsor:

Heat Biologics
Pelican Therapeutics, Inc.